Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297297 | 0.78 | ALDH1A1 (0.48) | ALDH1A1HPGDHTTSMN1; SMN2TSHR | |
| SCHEMBL841267 | 0.77 | ALDH1A1 (0.59) | ALDH1A1HPGDHTTSMN1; SMN2TSHR | |
| SCHEMBL28464748 | 0.74 | ALDH1A1 (0.50) | ALDH1A1HPGDHTTSMN1; SMN2TSHR | |
| SCHEMBL14909 | 0.74 | NFE2L2 (0.55) | ALDH1A1HPGDSMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL14421024 | 0.74 | ALDH1A1 (0.44) | ALDH1A1HPGDHTTSMN1; SMN2TSHR | |
| SCHEMBL29377009 | 0.74 | NFE2L2 (0.55) | ALDH1A1HPGDSMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL2331789 | 0.74 | ALDH1A1 (0.44) | ALDH1A1HPGDHTTSMN1; SMN2TSHR | |
| SCHEMBL15711501 | 0.74 | ALDH1A1 (0.44) | ALDH1A1HPGDHTTSMN1; SMN2TSHR | |
| SCHEMBL664369 | 0.74 | ALDH1A1 (0.44) | ALDH1A1HPGDHTTSMN1; SMN2TSHR | |
| SCHEMBL3625298 | 0.74 | ALDH1A1 (0.44) | ALDH1A1HPGDHTTSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115298175-B | Macrocyclic PAD4 inhibitors useful as immunosuppressants | 百时美施贵宝公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-116635393-A | Heterocyclic derivatives substituted with a middle or macrocyclic benzyl group and their use as orexin-2 receptor agonists | 欧瑞夏治疗有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116283799-A | Quinazoline methionine adenosyltransferase 2A inhibitors | 南京正大天晴制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115551862-A | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115298175-A | Macrocyclic PAD4 inhibitors useful as immunosuppressants | 百时美施贵宝公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-113227087-A | Macrocyclic compounds and their use in the treatment of disease | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-2480402-B1 | WETTABLE HYDROGEL MATERIALS FOR USE IN OPHTHALMIC APPLICATIONS AND METHODS | COOPERVISION INT HOLDING CO LP (BB) | 2017-01-25 | — | — | EP | disclosed |
| EP-2480928-B1 | MATERIALS FOR USE IN OPHTHALMIC APPLICATIONS AND METHODS | COOPERVISION INT HOLDING CO LP (BB) | 2017-01-25 | — | — | EP | disclosed |
| US-8979261-B2 | Silicone hydrogel ophthalmic devices molded in vinyl alcohol copolymer molds and related methods | COOPERVISION INTERNATIONAL HOLDING COMPANY, LP (BB) | 2015-03-17 | — | — | US | disclosed |
| EP-2480402-A2 | WETTABLE HYDROGEL MATERIALS FOR USE IN OPHTHALMIC APPLICATIONS AND METHODS | CooperVision International Holding Company, LP (BB) | 2012-08-01 | — | — | EP | disclosed |
| EP-2480928-A2 | MATERIALS FOR USE IN OPHTHALMIC APPLICATIONS AND METHODS | CooperVision International Holding Company, LP (BB) | 2012-08-01 | — | — | EP | disclosed |
| US-20120172486-A1 | Wettable Hydrogel Materials For Use In Ophthalmic Applications And Methods | COOPERVISION INTERNATIONAL HOLDING COMPANY, LP (BB) | 2012-07-05 | — | — | US | disclosed |
| US-8114887-B2 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-02-14 | — | — | US | disclosed |
| WO-2012013947-A1 | SILICONE HYDROGEL OPHTHALMIC DEVICES MOLDED IN VINYL ALCOHOL COPOLYMER MOLDS AND RELATED METHODS | GOODENOUGH NEIL (GB) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011037897-A2 | MATERIALS FOR USE IN OPHTHALMIC APPLICATIONS AND METHODS | COOPERVISION INTERNATIONAL HOLDING COMPANY, LP (BB) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011037893-A2 | WETTABLE HYDROGEL MATERIALS FOR USE IN OPHTHALMIC APPLICATIONS AND METHODS | COOPERVISION INTERNATIONAL HOLDING COMPANY, LP (BB) | 2011-03-31 | — | — | WO | disclosed |
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| EP-1804794-A2 | SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER S DISEASE | Merck & Co., Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044497-A2 | SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER’S DISEASE | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | BACE1, BACE2, APP | ALDH1A1 322/4885HPGD 393/4885HTT 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.